Search

Your search keyword '"Nasser, H."' showing total 58 results

Search Constraints

Start Over You searched for: Author "Nasser, H." Remove constraint Author: "Nasser, H." Publisher wiley Remove constraint Publisher: wiley
58 results on '"Nasser, H."'

Search Results

1. A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029

2. Relations of perceived injustice to psycho‐spiritual outcomes in advanced lung and prostate cancer: Examining the role of acceptance and meaning making

3. A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029

4. Relations of perceived injustice to psycho‐spiritual outcomes in advanced lung and prostate cancer: Examining the role of acceptance and meaning making

5. Survival outcomes and toxicity in patients 40 years old or older with relapsed metastatic germ cell tumors treated with high‐dose chemotherapy and peripheral blood stem cell transplantation

10. The exponentiated power Lomax distribution and its applications

12. High‐dose chemotherapy plus peripheral blood stem cell transplantation for patients with relapsed germ cell tumors and active brain metastases

14. Survival outcomes and toxicity in patients 40 years old or older with relapsed metastatic germ cell tumors treated with high‐dose chemotherapy and peripheral blood stem cell transplantation

16. Optimal control for a nonlinear mathematical model of tumor under immune suppression: A numerical approach

17. A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer

18. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179

19. Numerical solutions of nonlinear fractional Schrödinger equations using nonstandard discretizations

20. On the optimal control for fractional multi-strain TB model

22. A comparison of functional magnetic resonance imaging findings in children with and without a history of early exposure to general anesthesia

23. Tolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies

25. Support service use and interest in support services among distressed family caregivers of lung cancer patients

26. Solar cell generations over 40% efficiency

27. Band gap-voltage offset and energy production in next-generation multijunction solar cells

29. Recent advances in high-efficiencyIII-V multi-junction solar cells for space applications: ultra triple junction qualification

30. Lead‐induced developmental perturbations in hippocampal Sp1 DNA‐binding are prevented by zinc supplementation: in vivo evidence for Pb and Zn competition

31. Correlation between lead‐induced changes in cerebral ornithine decarboxylase and protein kinase C activities during development and in cultured PC 12 CELLS

34. Developmental profiles of ornithine decarboxylase activity in the hippocampus, neocortex and cerebellum: Modulation following lead exposure

35. Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology

37. S4‐03‐03: The 'LEARn' (Latent Early‐life Associated Regulation) model may explain the etiology of sporadic cases of Alzheimer's disease

38. S4‐03‐05: The environment, epigenetics and amyloidogenesis

39. S2–01–06: Genetics & epigenetic studies in AD

42. Lead (Pb) exposure and its effect on APP proteolysis and Aβ aggregation

45. P3-234: Early-life environment affects expression of genes invoved in Alzheimer's disease by an epigenetic mechanism

48. Recent advances in high‐efficiency III–V multi‐junction solar cells for space applications: ultra triple junction qualification

49. A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.

50. Focal epilepsy due to de novo SCN1A mutation.

Catalog

Books, media, physical & digital resources